1. PI3K/Akt/mTOR
    Cell Cycle/DNA Damage
    PI3K/Akt/mTOR
    PI3K/Akt/mTOR
  2. PI3K
    DNA-PK
    mTOR

LY3023414 (Synonyms: LY-3023414; LY 3023414)

Cat. No.: HY-12513 Purity: 99.70%
Data Sheet SDS Handling Instructions

LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).

For research use only. We do not sell to patients.
LY3023414 Chemical Structure

LY3023414 Chemical Structure

CAS No. : 1386874-06-1

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $110 In-stock
5 mg $100 In-stock
10 mg $180 In-stock
50 mg $720 In-stock
100 mg $1300 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02536586 Eli Lilly and Company Neoplasm September 2015 Phase 1
NCT02549989 Memorial Sloan Kettering Cancer Center|Eli Lilly and Company Endometrial Cancer|Recurrent Endometrial Cancer September 2015 Phase 2
NCT02575703 Eli Lilly and Company Healthy October 2015 Phase 1
NCT02443337 Eli Lilly and Company|SCRI Development Innovations, LLC Non-small Cell Lung Cancer Metastatic July 2015 Phase 2
NCT02818335 Eli Lilly and Company Healthy July 2016 Phase 1
NCT02407054 Eli Lilly and Company|Sarah Cannon Development Innovations Prostate Cancer Metastatic April 2015 Phase 2
NCT01655225 Eli Lilly and Company Advanced Cancer|Metastatic Cancer|Non-Hodgkin's Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer July 31, 2012 Phase 1
NCT02057133 Eli Lilly and Company Breast Neoplasms March 10, 2014 Phase 1
NCT02124148 Eli Lilly and Company Neoplasm Metastasis|Colorectal Neoplasms June 18, 2014 Phase 1
NCT02981342 Eli Lilly and Company Pancreatic Ductal Adenocarcinoma January 2017 Phase 2
NCT02079636 Eli Lilly and Company|Merck Sharp & Dohme Corp. Carcinoma, Non-small Cell Lung March 2014 Phase 1
NCT02784795 Eli Lilly and Company Solid Tumor|Breast Cancer|Colon Cancer|Cholangiocarcinoma|Soft Tissue Sarcoma November 2016 Phase 1
NCT03155620 National Cancer Institute (NCI) Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Lymphoma|Recurrent Central Nervous System Neoplasm|Recurrent Malignant Solid Neoplasm|Refractory Central Nervous System Neoplasm|Refractory Malignant Solid Neoplasm July 6, 2017 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.4601 mL 12.3007 mL 24.6015 mL
5 mM 0.4920 mL 2.4601 mL 4.9203 mL
10 mM 0.2460 mL 1.2301 mL 2.4601 mL
References
M.Wt

406.48

Formula

C₂₃H₂₆N₄O₃

CAS No.

1386874-06-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LY3023414
Cat. No.:
HY-12513
Quantity: